Published evidence of overall significant improvement in 2 Quality of Life (QOL), using a validated tool. Measurable evidence of significant improvement in 1 aspect(s) of QOL using a validated tool or evidence of lack of deterioration in overall QOL using a validated tool or clear evidence of major improvement in QOL without validated tool (eg clinically significant reduction in blood transfusion) Little or no evidence of improvement of QOL or no QOL data 0 collected in the trial evidence of major deterioration in QOL without a 1 validated tool (eg clinically significant increase in incidence of febrile neutropenia) Published evidence of deterioration in QOL using a validated Minus 2 tool. 3 Toxicity compared to the existing active standard therapy. Criteria Score Recorded Score Significant improvement 2 Improved 1 Equal 0 Worsened Minus 1 Significantly worsened Minus 2 4 Degree of clinical unmet need, i.e. a step change for the clinical setting concerned N.B. If there has been no score in section 1 of this tool, then no score can be assigned for this section Criteria Score Recorded Score or N/A No alternative treatment 3 Alternative Active standard treatment exists 0 5 Cost per QALY if available. The Cost per QALY calculated by NICE in the course of an – appraisal are the most accurate cost per QALY for use in England and Wales. Note that they often incorporate Patient Access Schemes which may or may not be available after a NICE ‘no’. QALY Score for Recorded score Independent Published Calculation £30-40,000 2 £40 -50,000 1 £50-60,000 0 £60-80,000 Minus 1
Published evidence of overall significant improvement in Quality of Life (QOL), using a validated tool. 2 Measurable evidence of significant improvement in aspect(s) of QOL using a validated tool or evidence of lack of deterioration in overall QOL using a validated tool or clear evidence of major improvement in QOL without validated tool (eg clinically significant reduction in blood transfusion) 1 Little or no evidence of improvement of QOL or no QOL data collected in the trial 0 evidence of major deterioration in QOL without a validated tool (eg clinically significant increase in incidence of febrile neutropenia) 1 Published evidence of deterioration in QOL using a validated tool. Minus 2 3 Toxicity compared to the existing active standard therapy. Criteria Score Recorded Score Significant improvement 2 Improved 1 Equal 0 Worsened Minus 1 Significantly worsened Minus 2 4 Degree of clinical unmet need, i.e. a step change for the clinical setting concerned N.B. If there has been no score in section 1 of this tool, then no score can be assigned for this section Criteria Score Recorded Score or N/A No alternative treatment 3 Alternative Active standard treatment exists 0 5 Cost per QALY – if available. The Cost per QALY calculated by NICE in the course of an appraisal are the most accurate cost per QALY for use in England and Wales. Note that they often incorporate Patient Access Schemes which may or may not be available after a NICE ‘no’. QALY Score for Independent Published Calculation Recorded score £30-40,000 2 £40 -50,000 1 £50-60,000 0 £60-80,000 Minus 1
Appendix%20E%20National%20Prioritisation%20tool.docx